Top 5 Stocks to Buy Now
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free ZVRA Stock Alerts

Zevra Therapeutics (ZVRA) Financials

Zevra Therapeutics logo
$13.00 +0.35 (+2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$12.89 -0.11 (-0.85%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Zevra Therapeutics

Annual Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -55 -17 -43 -56 -25 -13 -63 -27 -46 -106 83
Consolidated Net Income / (Loss)		 -55 -17 -43 -56 -25 -13 -8.56 -27 -46 -106 83
Net Income / (Loss) Continuing Operations		 -55 -17 -43 -56 -25 -13 -8.56 -27 -46 -106 83
Total Pre-Tax Income 		-55 -17 -43 -57 -25 -13 -8.52 -27 -46 -90 87
Total Operating Income		 -23 -37 -33 -56 -20 -5.61 7.73 -43 -50 -87 -63
Total Gross Profit		 0.00 0.00 0.00 0.00 13 13 27 9.94 25 16 90
Total Revenue		 0.00 0.00 0.00 0.00 13 13 29 10 27 24 106
Operating Revenue		 0.00 0.00 0.00 0.00 13 13 29 10 27 24 106
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 2.06 0.22 2.17 7.42 16
Operating Cost of Revenue		 - - - - - - 2.06 0.22 2.17 7.42 16
Total Operating Expenses		 23 37 33 56 33 19 19 53 75 103 153
Selling, General & Admin Expense		 8.88 14 13 13 11 7.92 8.70 15 34 55 78
Research & Development Expense		 14 20 21 42 19 8.84 10 37 40 42 13
Amortization Expense		 - - - - - - - - 0.77 6.24 3.86
Impairment Charge		 - - - - - - - - - 0.00 59
Total Other Income / (Expense), net		 -32 21 -10 -0.69 -4.21 -7.19 -16 16 3.56 -3.14 150
Interest Expense		 4.58 12 7.34 7.09 6.21 7.00 16 -1.18 -3.04 5.18 1.03
Other Income / (Expense), net		 -27 32 -3.09 5.98 2.00 -0.18 -0.03 15 0.52 2.04 151
Income Tax Expense		 0.03 -0.02 -0.04 -0.13 -0.02 -0.03 0.03 -0.03 0.00 15 3.45
Basic Earnings per Share		 ($7.42) ($1.13) ($2.96) ($3.15) ($13.23) ($3.21) ($2.11) ($0.78) ($1.30) ($2.28) $1.40
Weighted Average Basic Shares Outstanding		 7.37M 14.60M 14.65M 17.93M 1.85M 3.98M 29.77M 34.49M 35.45M 46.25M 55.31M
Diluted Earnings per Share		 ($7.42) ($1.13) ($2.96) ($3.15) ($13.23) ($3.21) - - - ($2.28) $1.35
Weighted Average Diluted Shares Outstanding		 7.37M 14.60M 14.65M 17.93M 1.85M 3.98M 34.42M 34.54M 43.43M 46.25M 57.26M
Weighted Average Basic & Diluted Shares Outstanding		 7.37M 14.60M 14.65M 17.93M 1.85M 3.98M 34.42M 34.54M 43.43M 54.12M 58.71M

Quarterly Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -10 -20 -17 -20 -33 -36 -3.10 75 -0.54 12 38
Consolidated Net Income / (Loss)		 -10 -20 -17 -20 -33 -36 -3.10 75 -0.54 12 38
Net Income / (Loss) Continuing Operations		 -10 -20 -17 -20 -33 -36 -3.10 75 -0.54 12 38
Total Pre-Tax Income 		-10 -20 -17 -20 -33 -20 -1.92 77 -0.98 13 45
Total Operating Income		 -15 -15 -20 -24 -27 -15 -5.36 -71 4.14 9.32 52
Total Gross Profit		 2.75 12 3.25 0.88 1.39 11 19 14 25 33 34
Total Revenue		 2.90 13 3.43 4.45 3.70 12 20 26 26 34 36
Operating Revenue		 2.90 13 3.43 4.45 3.70 12 20 26 26 34 36
Total Cost of Revenue		 0.14 1.23 0.18 3.57 2.30 1.37 1.35 12 1.24 1.52 1.90
Operating Cost of Revenue		 0.14 1.23 0.18 3.57 2.30 1.37 1.35 12 1.24 1.52 1.90
Total Operating Expenses		 18 27 24 25 29 26 24 85 21 23 -18
Selling, General & Admin Expense		 5.82 15 9.93 13 16 16 20 21 17 20 21
Research & Development Expense		 12 11 12 11 11 8.35 3.26 3.43 3.43 2.62 4.39
Amortization Expense		 0.00 0.77 1.53 1.55 1.55 1.62 1.62 1.62 0.32 0.32 0.32
Other Special Charges / (Income)		 - - - - - - 0.00 - - - -43
Total Other Income / (Expense), net		 5.17 -4.74 3.79 3.94 -5.92 -4.95 3.45 148 -5.12 3.35 -7.34
Interest Expense		 -1.37 0.55 -0.19 1.84 1.26 2.27 1.43 -0.37 -0.26 0.24 0.88
Other Income / (Expense), net		 3.80 -4.19 3.60 5.78 -4.66 -2.69 4.87 148 -5.38 3.59 -6.46
Income Tax Expense		 0.18 - -0.07 0.07 0.00 15 1.18 2.20 -0.43 0.50 6.91
Basic Earnings per Share		 ($0.30) ($0.54) ($0.40) ($0.48) ($0.69) ($0.71) ($0.06) $1.24 ($0.01) $0.23 $0.62
Weighted Average Basic Shares Outstanding		 34.72M 35.45M 41.78M 41.90M 47.81M 46.25M 54.10M 54.78M 55.95M 55.31M 58.41M
Diluted Earnings per Share		 - - - ($0.48) ($0.69) - ($0.06) $1.21 ($0.01) - $0.60
Weighted Average Diluted Shares Outstanding		 36.22M 43.43M 41.85M 41.90M 47.81M 54.12M 54.10M 56.32M 55.95M 57.26M 60.23M
Weighted Average Basic & Diluted Shares Outstanding		 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M 54.68M 56.14M 56.30M 58.71M 59.12M

Annual Cash Flow Statements for Zevra Therapeutics

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 18 -14 -5.89 7.15 -16 0.77 108 -47 -22 -9.26 29
Net Cash From Operating Activities		 -20 -30 -33 -54 -24 -1.94 10 -19 -34 -70 -1.60
Net Cash From Continuing Operating Activities		 -20 -30 -33 -54 -24 -1.94 10 -19 -34 -70 -1.60
Net Income / (Loss) Continuing Operations		 -55 -17 -43 -56 -25 -13 -8.56 -27 -46 -106 83
Consolidated Net Income / (Loss)		 -55 -17 -43 -56 -25 -13 -8.56 -27 -46 -106 83
Depreciation Expense		 0.08 0.18 0.34 0.32 0.30 0.27 0.26 0.94 1.01 6.39 4.05
Amortization Expense		 4.58 3.84 3.78 1.62 1.66 2.31 0.15 - 0.00 -0.89 -3.13
Non-Cash Adjustments To Reconcile Net Income		 30 -30 7.61 2.61 7.67 7.73 19 7.79 8.74 38 -59
Changes in Operating Assets and Liabilities, net		 2.54 -0.72 0.20 -1.19 -3.41 0.52 -0.49 -0.68 2.77 -7.19 -27
Net Cash From Investing Activities		 -19 -46 27 33 3.23 -0.03 -16 -37 -17 -22 18
Net Cash From Continuing Investing Activities		 -19 -46 27 33 3.23 -0.03 -16 -37 -17 -22 18
Purchase of Property, Plant & Equipment		 -0.14 -0.64 -0.18 - -0.03 -0.03 -0.10 -0.09 -0.30 0.00 -0.84
Acquisitions		 - - - - - - 0.00 -14 -30 -6.00 0.00
Purchase of Investments		 -19 -90 -27 - - 0.00 -15 -24 -46 -41 -310
Sale of Property, Plant & Equipment		 - - - 0.02 - - - - - 0.00 0.45
Sale and/or Maturity of Investments		 0.00 45 55 33 3.26 - - 1.33 59 25 179
Other Investing Activities, net		 - - - - - - - - - 0.00 150
Net Cash From Financing Activities		 57 61 -0.20 28 4.94 2.74 113 8.35 28 82 12
Net Cash From Continuing Financing Activities		 57 61 -0.20 28 4.94 2.74 75 8.35 28 82 12
Repayment of Debt		 0.00 - -0.21 -0.19 -0.30 -0.03 -41 -0.02 -18 -45 0.00
Issuance of Debt		 0.35 104 0.00 24 5.45 3.08 0.00 13 42 60 0.62
Issuance of Common Equity		 62 0.98 0.00 4.83 - 0.00 37 0.32 6.32 65 0.00
Other Financing Activities, net		 0.41 0.14 0.00 0.07 -0.21 -0.23 80 -0.03 0.69 2.34 11
Effect of Exchange Rate Changes		 - - - - - - 0.00 0.20 - 0.45 0.03
Cash Interest Paid		 0.00 3.29 5.72 5.54 5.36 0.08 0.22 0.32 0.46 5.26 5.33

Quarterly Cash Flow Statements for Zevra Therapeutics

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -23 -0.22 -0.20 -3.59 15 -20 3.56 10 6.73 7.97 33
Net Cash From Operating Activities		 -4.63 -16 -16 -19 -18 -16 -8.22 -3.60 4.71 5.52 6.14
Net Cash From Continuing Operating Activities		 -4.63 -16 -16 -19 -18 -16 -8.22 -3.60 4.71 5.52 6.14
Net Income / (Loss) Continuing Operations		 -10 -20 -17 -20 -33 -36 -3.10 75 -0.54 12 38
Consolidated Net Income / (Loss)		 -10 -20 -17 -20 -33 -36 -3.10 75 -0.54 12 38
Depreciation Expense		 0.06 0.79 1.56 1.56 1.62 1.65 1.65 1.65 0.39 0.36 0.37
Amortization Expense		 - - 0.00 - - - -0.31 -0.76 -1.21 -0.86 -0.62
Non-Cash Adjustments To Reconcile Net Income		 -1.31 4.79 0.06 2.37 11 24 0.54 -75 9.13 3.97 -37
Changes in Operating Assets and Liabilities, net		 6.99 -1.85 -1.16 -3.12 2.46 -5.37 -7.01 -4.60 -3.06 -10 5.19
Net Cash From Investing Activities		 -44 11 15 -0.13 -31 -5.47 11 12 -4.58 0.23 80
Net Cash From Continuing Investing Activities		 -44 11 15 -0.13 -31 -5.47 11 12 -4.58 0.23 80
Purchase of Property, Plant & Equipment		 -0.17 -0.07 0.00 - - - -0.10 -0.21 -0.55 0.03 -0.04
Purchase of Investments		 -54 25 0.00 - -41 0.33 -7.36 -150 -65 -87 -58
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - -0.14 0.04
Divestitures		 - - - - - - 0.00 - - - 44
Sale and/or Maturity of Investments		 9.50 16 15 - 10 0.20 18 13 61 88 94
Net Cash From Financing Activities		 26 5.00 1.22 15 65 0.80 1.61 1.38 6.53 2.55 -53
Net Cash From Continuing Financing Activities		 26 5.00 1.22 15 65 0.80 1.61 1.38 6.53 2.55 -53
Repayment of Debt		 0.21 -4.73 - -45 - - 0.00 - - - -60
Issuance of Common Equity		 0.05 6.11 1.22 0.48 65 -0.89 1.98 - - -3.52 0.75
Other Financing Activities, net		 -0.00 - 0.00 0.65 - 1.68 -0.37 0.97 3.01 5.86 6.54
Effect of Exchange Rate Changes		 - - - - - - -0.37 - - - 0.23
Cash Interest Paid		 0.20 - 0.14 2.00 1.53 1.59 1.31 1.32 1.37 1.34 1.37

Annual Balance Sheets for Zevra Therapeutics

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 55 85 52 27 11 11 133 115 172 178 285
Total Current Assets		 54 74 46 24 6.97 8.38 115 93 87 86 223
Cash & Equivalents		 32 17 11 18 3.22 4.21 112 65 43 34 62
Short-Term Investments		 19 51 31 3.26 - - 0.00 17 25 36 129
Accounts Receivable		 0.00 5.00 2.01 0.14 1.87 2.58 1.53 8.30 17 11 23
Inventories, net		 - - - - - - - - 0.00 1.97 1.74
Prepaid Expenses		 2.76 0.49 1.66 1.91 1.55 1.48 1.18 1.69 1.82 4.05 7.00
Plant, Property, & Equipment, net		 0.40 1.97 2.00 1.75 1.47 1.04 0.88 0.79 0.74 0.36 0.49
Total Noncurrent Assets		 0.11 8.56 4.56 1.27 2.06 1.79 17 22 85 92 61
Long-Term Investments		 0.00 8.20 3.25 - - 0.00 15 20 0.00 6.01 48
Goodwill		 - - - - - - - 0.00 4.70 4.70 4.70
Intangible Assets		 - - - - - - - 0.00 69 69 6.42
Other Noncurrent Operating Assets		 0.11 0.36 0.21 0.56 2.06 1.79 1.58 1.71 11 12 2.23
Total Liabilities & Shareholders' Equity		 55 85 52 27 11 11 133 115 172 178 285
Total Liabilities		 65 104 110 93 85 78 5.82 40 110 138 130
Total Current Liabilities		 8.34 6.64 12 12 5.43 7.54 4.23 12 74 34 39
Accounts Payable		 4.91 6.44 7.88 8.34 4.91 6.65 3.04 6.17 28 25 12
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 14
Other Current Liabilities		 2.04 0.04 0.11 0.12 0.52 0.50 1.19 5.85 7.62 8.61 14
Total Noncurrent Liabilities		 56 97 98 81 80 70 1.59 28 37 104 91
Long-Term Debt		 7.41 91 89 78 77 68 0.00 13 5.07 60 62
Noncurrent Deferred Revenue		 - - - - - - - - 0.00 14 7.03
Other Noncurrent Operating Liabilities		 49 5.11 8.50 2.81 2.19 2.04 1.59 15 32 30 22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -10 -19 -58 -67 -74 -66 127 75 62 40 155
Total Preferred & Common Equity		 -10 -19 -58 -67 -74 -66 127 75 62 40 155
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -10 -19 -58 -67 -74 -66 127 75 62 40 155
Common Stock		 95 103 107 155 171 192 397 436 473 555 588
Retained Earnings		 -105 -121 -165 -221 -246 -258 -267 -354 -400 -505 -422
Treasury Stock		 - - - - - - -2.81 -7.54 -11 -11 -11
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - 0.00 0.11 -0.04 0.63 -0.76

Quarterly Balance Sheets for Zevra Therapeutics

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 120 107 106 139 151 144 192 173 256 270 279
Total Current Assets		 85 104 103 137 63 61 99 82 226 225 230
Cash & Equivalents		 70 40 66 43 43 39 54 37 48 54 96
Short-Term Investments		 5.83 55 21 40 9.87 10.00 35 25 155 145 105
Accounts Receivable		 6.58 7.82 14 9.93 8.31 8.95 7.79 13 18 17 22
Inventories, net		 - - - - - - - 2.56 1.11 1.37 2.31
Prepaid Expenses		 2.66 1.17 2.02 1.66 1.87 2.69 2.28 3.77 4.35 7.40 4.94
Plant, Property, & Equipment, net		 0.85 0.74 0.69 0.64 0.70 0.68 0.61 0.42 0.60 0.49 0.43
Total Noncurrent Assets		 34 1.57 1.40 1.33 88 83 92 91 29 45 48
Long-Term Investments		 31 0.00 0.00 0.00 - - 6.11 6.09 15 31 36
Goodwill		 - - - - 4.70 4.70 4.70 4.70 4.70 4.70 4.70
Intangible Assets		 - - - - 68 66 71 67 7.05 6.74 6.11
Other Noncurrent Operating Assets		 2.10 1.57 1.40 1.33 15 12 10 13 2.50 2.21 1.23
Total Liabilities & Shareholders' Equity		 120 107 106 139 151 144 192 173 256 270 279
Total Liabilities		 26 35 37 72 102 112 122 132 139 137 73
Total Current Liabilities		 8.43 16 18 22 30 30 34 27 29 26 47
Accounts Payable		 4.28 10 11 13 23 20 24 18 16 11 12
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 20
Other Current Liabilities		 4.15 5.52 7.74 8.63 7.12 10.00 10 9.16 13 15 15
Total Noncurrent Liabilities		 17 20 19 50 73 81 87 105 110 111 26
Long-Term Debt		 13 13 13 44 43 58 59 60 61 61 0.00
Noncurrent Deferred Revenue		 - - - - - - - 16 17 17 6.87
Other Noncurrent Operating Liabilities		 4.53 6.66 6.06 5.92 30 23 28 28 32 32 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 94 71 68 67 49 32 70 41 117 133 206
Total Preferred & Common Equity		 94 71 68 67 49 32 70 41 117 133 206
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 94 71 68 67 49 32 70 41 117 133 206
Common Stock		 401 403 405 418 476 479 550 560 564 581 603
Retained Earnings		 -300 -320 -325 -339 -416 -436 -470 -508 -434 -434 -384
Treasury Stock		 -7.54 -11 -11 -11 -11 -11 -11 -11 -11 -11 -11
Accumulated Other Comprehensive Income / (Loss)		 0.20 -0.06 -0.23 -0.22 0.14 0.42 -0.12 -0.08 -2.43 -2.42 -1.80

Annual Metrics And Ratios for Zevra Therapeutics

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 14,448,826.00 14,646,982.00 14,657,430.00 26,455,352.00 33,223,877.00 72,544,837.00 35,319,426.00 - - - 56,297,535.00
DEI Adjusted Shares Outstanding		 14,448,826.00 14,646,982.00 14,657,430.00 26,455,352.00 33,223,877.00 72,544,837.00 35,319,426.00 - - - 56,297,535.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.78 -1.13 -2.96 -2.13 -0.74 -0.18 -1.78 - - - 1.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 3.50% 115.61% -64.53% 170.26% -14.02% 350.91%
EBITDA Growth		 -117.61% 97.79% -3,120.92% -48.39% 65.87% 80.37% 352.26% -433.40% -77.83% -65.27% 211.54%
EBIT Growth		 -111.65% 89.98% -626.67% -36.95% 63.27% 68.41% 232.97% -463.27% -75.42% -73.08% 203.23%
NOPAT Growth		 -38.75% -64.29% 10.98% -67.54% 63.62% 72.42% 237.80% -650.72% -16.54% -75.40% 0.76%
Net Income Growth		 -123.53% 69.79% -162.69% -30.15% 56.57% 47.97% 32.95% -212.94% -72.00% -129.13% 178.88%
EPS Growth		 27.75% 84.77% -161.95% -6.42% -320.00% 75.74% 0.00% 0.00% 0.00% 0.00% 159.21%
Operating Cash Flow Growth		 -38.15% -46.89% -11.18% -63.76% 56.21% 91.83% 638.37% -279.30% -79.17% -107.74% 97.71%
Free Cash Flow Firm Growth		 -51.12% -1,009.33% 78.00% -159.37% 51.45% 90.57% 291.98% -512.15% -457.68% 44.91% 69.65%
Invested Capital Growth		 -85.29% 92.82% -180.99% 35.01% 95.22% -595.45% 71.68% -2,196.46% 347.16% -35.86% -194.26%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 12.00% 8.05% 0.76% -5.22% 65.80% -3.58% 26.17%
EBITDA Q/Q Growth		 5.71% -24.41% -0.53% 8.06% -2.86% 43.29% -17.51% 24.62% -105.40% 1.50% 50.52%
EBIT Q/Q Growth		 5.05% -1.35% -2.09% 9.56% -3.46% 30.61% -12.86% 23.49% -105.15% 1.44% 54.67%
NOPAT Q/Q Growth		 0.89% -10.48% 7.45% -2.04% 19.28% 17.58% 5.06% -17.93% -13.35% -0.30% -4.68%
Net Income Q/Q Growth		 4.60% -4.64% -1.47% 8.70% -3.61% 8.47% 20.11% 24.00% -125.65% -17.67% 135.61%
EPS Q/Q Growth		 30.00% 67.62% -78.31% 27.59% -4,988.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 2.69% -11.03% 6.82% -23.05% 37.09% 51.26% 2.06% -23.93% -53.56% -0.13% 93.16%
Free Cash Flow Firm Q/Q Growth		 0.00% -7.31% 39.92% -49.40% 41.54% 51.47% -1.87% 36.06% -45.92% 27.76% -227.39%
Invested Capital Q/Q Growth		 7.87% 65.34% -22.88% 62.33% 7.56% -112.70% -377.78% -1,864.08% 32.15% -28.71% 37.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 92.81% 97.82% 92.09% 68.59% 84.52%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -127.57% -24.19% 28.31% -266.11% -175.10% -336.55% 83.25%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -158.40% -42.21% 26.98% -418.91% -180.63% -368.47% -59.12%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -142.84% -43.60% 26.89% -275.40% -178.76% -359.83% 82.38%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -191.00% -96.03% -29.86% -263.48% -167.69% -446.85% 78.17%
Tax Burden Percent		 100.05% 99.91% 99.90% 99.78% 99.91% 99.73% 100.40% 99.88% 100.00% 117.05% 96.02%
Interest Burden Percent		 109.08% 329.50% 119.12% 113.35% 133.84% 220.85% -110.62% 95.79% 93.81% 106.09% 98.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.98%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -316.15% -201.14% -8,894.55%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -296.46% 16.61% -9,043.45%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 248.92% -6.70% 8,980.21%
Return on Equity (ROE)		 317.61% 114.63% 113.86% 91.01% 34.78% 18.12% -28.19% -26.48% -67.23% -207.84% 85.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -234.58% -157.45% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -98.46% -53.35% 10.69% -22.54% -34.13% -48.49% 37.90%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -131.65% -117.52% -11.87% -21.57% -32.02% -60.21% 35.96%
Return on Common Equity (ROCE)		 540.97% 114.63% 113.86% 91.01% 34.78% 18.12% -28.19% -26.48% -67.23% -207.84% 85.66%
Return on Equity Simple (ROE_SIMPLE)		 540.10% 88.34% 75.43% 84.83% 32.93% 19.21% -6.73% -35.64% -74.44% -266.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -26 -23 -39 -14 -3.93 5.41 -30 -35 -61 -60
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -110.88% -29.55% 18.88% -293.23% -126.44% -257.93% -56.77%
Net Nonoperating Expense Percent (NNEP)		 -166.01% 70.46% 64.80% 32.53% 15.38% 12.78% -43.88% 2.78% -19.69% -217.75% 148.91%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -33.19% -61.41% -27.91%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.19% 2.18% 7.91% 31.41% 15.48%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 84.24% 59.61% 30.37% 148.00% 124.96% 232.37% 72.90%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 151.22% 66.55% 35.47% 368.72% 144.95% 178.28% 11.97%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 258.40% 142.21% 65.84% 516.72% 272.72% 437.06% 143.64%
Earnings before Interest and Taxes (EBIT)		 -50 -5.02 -36 -50 -18 -5.79 7.70 -28 -49 -85 88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -1.00 -32 -48 -16 -3.22 8.11 -27 -48 -79 89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 2.42 2.11 3.83 11.22 3.26
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 2.42 2.11 0.00 0.00 3.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.98 1.12 10.74 15.59 8.64 18.85 4.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.06
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.50%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.75 18.14 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 6.76 5.95 6.28 6.72 7.73 18.18 3.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 22.18 0.00 0.00 0.00 3.69
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 23.35 0.00 0.00 0.00 3.73
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 33.24 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 17.23 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 29.60 0.00 0.00 0.00 0.00 0.00 47.77 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.87 -4.92 -1.63 -1.23 -1.04 -1.03 0.00 0.17 0.69 1.50 0.40
Long-Term Debt to Equity		 -0.73 -4.91 -1.56 -1.18 -1.04 -1.02 0.00 0.17 0.08 1.50 0.40
Financial Leverage		 1.35 0.96 -0.81 -0.86 -0.95 -0.98 -1.05 -1.08 -0.84 -0.40 -0.99
Leverage Ratio		 -1.98 -4.84 -1.80 -0.64 -0.26 -0.15 2.37 1.23 2.10 3.45 2.38
Compound Leverage Factor		 -2.16 -15.95 -2.15 -0.72 -0.35 -0.34 -2.63 1.18 1.97 3.66 2.35
Debt to Total Capital		 -670.24% 125.51% 259.92% 529.96% 2,679.01% 3,376.37% 0.00% 14.56% 40.87% 60.00% 28.59%
Short-Term Debt to Total Capital		 -106.16% 0.21% 9.79% 22.91% 0.00% 19.24% 0.00% 0.00% 36.03% 0.00% 0.00%
Long-Term Debt to Total Capital		 -564.08% 125.30% 250.13% 507.05% 2,679.01% 3,357.13% 0.00% 14.56% 4.84% 60.00% 28.59%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 770.24% -25.51% -159.92% -429.96% -2,579.01% -3,276.37% 100.00% 85.44% 59.13% 40.00% 71.41%
Debt to EBITDA		 -0.19 -91.62 -2.89 -1.71 -4.72 -21.29 0.00 -0.47 -0.89 -0.75 0.70
Net Debt to EBITDA		 0.94 -14.86 -1.48 -1.26 -4.53 -19.94 0.00 3.33 0.52 0.20 -2.00
Long-Term Debt to EBITDA		 -0.16 -91.46 -2.78 -1.64 -4.72 -21.17 0.00 -0.47 -0.11 -0.75 0.70
Debt to NOPAT		 -0.55 -3.51 -4.00 -2.10 -5.43 -17.43 0.00 -0.43 -1.23 -0.98 -1.02
Net Debt to NOPAT		 2.66 -0.57 -2.06 -1.54 -5.21 -16.33 0.00 3.02 0.72 0.26 2.93
Long-Term Debt to NOPAT		 -0.46 -3.50 -3.85 -2.01 -5.43 -17.33 0.00 -0.43 -0.15 -0.98 -1.02
Altman Z-Score		 -2.05 -0.99 -5.58 -16.91 -37.01 -32.60 30.29 -1.80 -2.65 -3.13 2.42
Noncontrolling Interest Sharing Ratio		 -70.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.48 11.20 3.99 1.98 1.28 1.11 27.20 7.72 1.18 2.53 5.68
Quick Ratio		 6.15 10.96 3.84 1.82 0.94 0.90 26.92 7.58 1.15 2.35 5.46
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8.26 -75 -17 -43 -21 -1.96 3.77 -16 -87 -48 -14
Operating Cash Flow to CapEx		 -15,013.33% -4,630.17% -18,287.29% 0.00% -91,296.15% -5,875.76% 10,234.31% -20,125.81% -11,329.39% 0.00% -412.92%
Free Cash Flow to Firm to Interest Expense		 1.80 -6.33 -2.25 -6.05 -3.35 -0.28 0.23 0.00 0.00 -9.21 -14.03
Operating Cash Flow to Interest Expense		 -4.43 -2.51 -4.51 -7.65 -3.83 -0.28 0.64 0.00 0.00 -13.46 -1.55
Operating Cash Flow Less CapEx to Interest Expense		 -4.45 -2.56 -4.54 -7.65 -3.83 -0.28 0.64 0.00 0.00 -13.46 -1.93
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.69 1.22 0.40 0.08 0.19 0.13 0.46
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 12.81 5.98 13.95 2.07 2.14 1.69 6.31
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.89
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 7.96 10.59 29.80 12.11 35.90 43.25 252.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.05 0.13 0.28 0.89
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 28.50 61.03 26.16 176.50 170.64 215.53 57.88
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.08
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 858.43 7,568.82 2,903.54 1,325.23 410.29
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 28.50 61.03 -832.27 -7,392.32 -2,732.90 -1,109.70 -311.33
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -53 -3.78 -11 -6.90 -0.33 -2.30 -0.65 -15 37 24 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -3.55 -10.12 -19.46 -1.30 2.50 0.78 156.69
Increase / (Decrease) in Invested Capital		 -24 49 -6.84 3.72 6.57 -1.97 1.65 -14 52 -13 -46
Enterprise Value (EV)		 244 58 107 107 87 79 180 68 212 429 327
Market Capitalization		 287 43 59 47 13 15 308 158 237 445 504
Book Value per Share		 ($0.70) ($1.28) ($3.92) ($2.52) ($2.24) ($0.92) $3.60 $2.18 $1.71 $0.74 $2.75
Tangible Book Value per Share		 ($0.70) ($1.28) ($3.92) ($2.52) ($2.24) ($0.92) $3.60 $2.18 ($0.33) ($0.64) $2.55
Total Capital		 -1.31 73 36 15 2.89 2.03 127 88 105 99 217
Total Debt		 8.81 92 93 82 77 68 0.00 13 43 60 62
Total Long-Term Debt		 7.41 92 90 79 77 68 0.00 13 5.07 60 62
Net Debt		 -43 15 48 60 74 64 -128 -90 -25 -16 -177
Capital Expenditures (CapEx)		 0.14 0.64 0.18 -0.02 0.03 0.03 0.10 0.09 0.30 0.00 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.19 -0.99 -4.32 -6.41 -1.68 -3.09 -1.52 -2.04 -17 -18 -7.28
Debt-free Net Working Capital (DFNWC)		 47 68 38 15 1.54 1.24 111 81 51 52 184
Net Working Capital (NWC)		 46 68 34 12 1.54 0.85 111 81 13 52 184
Net Nonoperating Expense (NNE)		 39 -9.72 20 17 10 8.83 14 -3.02 11 45 -144
Net Nonoperating Obligations (NNO)		 -43 15 47 60 74 64 -128 -90 -25 -16 -177
Total Depreciation and Amortization (D&A)		 4.66 4.01 4.12 1.94 1.96 2.58 0.41 0.94 1.01 5.50 0.93
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -13.05% -23.22% -5.31% -20.04% -61.25% -74.26% -6.84%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 12.00% 9.30% 386.83% 795.31% 185.42% 220.07% 172.57%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 12.00% 6.37% 386.83% 795.31% 48.13% 220.07% 172.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.42) ($1.13) ($2.96) ($3.15) ($0.83) ($3.21) ($2.11) ($1.20) ($1.30) ($2.28) $1.40
Adjusted Weighted Average Basic Shares Outstanding		 14.50M 14.65M 15.10M 26.46M 50.68M 28.38M 29.77M 34.49M 35.45M 46.25M 55.31M
Adjusted Diluted Earnings per Share		 ($7.42) ($1.13) ($2.96) ($3.15) ($0.83) ($3.21) ($2.11) $0.00 $0.00 $0.00 $1.35
Adjusted Weighted Average Diluted Shares Outstanding		 14.50M 14.65M 15.10M 26.46M 50.68M 28.38M 29.77M 34.54M 43.43M 54.12M 57.26M
Adjusted Basic & Diluted Earnings per Share		 ($7.42) ($1.13) ($2.96) ($3.15) ($0.83) ($3.21) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.37M 14.60M 14.65M 17.93M 29.65M 3.98M 34.42M 34.54M 43.43M 54.12M 58.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -26 -23 -39 -14 -3.93 5.41 -30 -35 -61 -4.06
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -110.88% -29.55% 18.88% -293.23% -126.44% -257.93% -3.82%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -191.17% -96.28% -29.74% -263.80% -167.69% -381.76% 81.41%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10.94 -0.42 -4.97 -7.05 -2.96 -0.83 0.48 0.00 0.00 -16.42 85.07
NOPAT to Interest Expense		 -3.49 -2.21 -3.18 -5.52 -2.29 -0.56 0.33 0.00 0.00 -11.77 -58.62
EBIT Less CapEx to Interest Expense		 -10.97 -0.48 -4.99 -7.04 -2.96 -0.83 0.47 0.00 0.00 -16.42 84.70
NOPAT Less CapEx to Interest Expense		 -3.52 -2.27 -3.21 -5.52 -2.30 -0.57 0.33 0.00 0.00 -11.77 -59.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.33% 0.00% -0.66% -15.64% -17.64% -7.49% 0.00% 0.00%

Quarterly Metrics And Ratios for Zevra Therapeutics

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 54,115,869.00 54,679,641.00 56,135,091.00 56,297,535.00 58,711,584.00
DEI Adjusted Shares Outstanding		 - - - - - - 54,115,869.00 54,679,641.00 56,135,091.00 56,297,535.00 58,711,584.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.06 1.37 -0.01 0.22 0.65
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.73% 538.97% 7.84% -47.47% 27.63% -6.79% 495.65% 481.73% 605.36% 183.36% 77.54%
EBITDA Growth		 -81.25% -403.37% -8.67% -319.18% -163.87% 11.34% 105.57% 570.63% 93.22% 171.54% 5,225.44%
EBIT Growth		 -71.47% -432.54% -19.08% -350.04% -176.44% 6.43% 97.09% 524.85% 96.12% 171.28% 9,403.87%
NOPAT Growth		 -131.87% -28.17% -59.66% -280.60% -77.73% -1.71% 73.83% -314.30% 115.17% 182.91% 1,274.91%
Net Income Growth		 -56.70% -445.95% -25.76% -674.39% -220.49% -79.67% 81.36% 474.94% 98.36% 134.04% 1,322.65%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 352.08% 98.55% 0.00% 1,100.00%
Operating Cash Flow Growth		 29.86% -262.12% -299.63% -119.54% -291.98% -0.57% 49.14% 81.16% 125.96% 133.94% 174.70%
Free Cash Flow Firm Growth		 -982.07% -1,140.65% -1,584.23% -9,182.88% 38.15% 103.90% 104.59% 119.14% 395.18% 2,152.67% 3,536.60%
Invested Capital Growth		 3,773.42% 347.16% 456.55% 774.15% 18.89% -35.86% -17.16% -195.74% -208.15% -194.26% -195.57%
Revenue Q/Q Growth		 -65.82% 346.29% -73.49% 29.90% -16.95% 225.93% 69.40% 26.86% 0.70% 30.93% 6.14%
EBITDA Q/Q Growth		 -192.99% -61.37% -2.99% -7.37% -84.43% 45.78% 104.92% 8,977.73% -102.66% 702.87% 266.13%
EBIT Q/Q Growth		 -188.83% -67.31% -7.79% -6.69% -77.42% 43.37% 97.29% 15,687.98% -101.62% 1,141.32% 254.07%
NOPAT Q/Q Growth		 -145.75% 1.35% -35.16% -16.15% -14.76% 43.54% 65.22% -1,738.54% 104.20% 208.49% 392.92%
Net Income Q/Q Growth		 -302.91% -91.88% -2.52% -19.87% -66.75% -7.57% 91.33% 2,510.68% -100.73% 2,336.21% 211.47%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.83% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 46.83% -249.14% -0.04% -18.21% 5.07% 10.42% 49.40% 56.20% 230.77% 17.14% 11.35%
Free Cash Flow Firm Q/Q Growth		 -5,586.88% -58.32% -3.16% 0.06% 62.11% 110.00% 21.20% 316.92% 484.43% -23.72% 95.66%
Invested Capital Q/Q Growth		 552.99% 32.15% 5.98% 6.26% -20.11% -28.71% 36.88% -222.81% 9.75% 37.87% -38.79%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 95.03% 90.50% 94.89% 19.69% 37.67% 88.66% 93.41% 52.17% 95.25% 95.55% 94.76%
EBITDA Margin		 -397.24% -143.63% -447.42% -369.81% -821.24% -136.62% 4.18% 299.19% -7.90% 36.36% 125.42%
Operating Margin		 -530.71% -117.31% -598.13% -534.84% -739.00% -128.01% -26.28% -274.48% 15.90% 27.30% 143.97%
EBIT Margin		 -399.38% -149.72% -493.02% -404.92% -865.01% -150.30% -2.41% 295.73% -4.75% 37.81% 126.12%
Profit (Net Income) Margin		 -358.10% -153.96% -485.31% -447.85% -899.19% -296.76% -15.19% 288.66% -2.09% 35.65% 104.61%
Tax Burden Percent		 101.74% 100.00% 99.58% 100.35% 100.00% 175.47% 161.66% 97.14% 55.68% 96.04% 84.57%
Interest Burden Percent		 88.13% 102.83% 98.85% 110.21% 103.95% 112.52% 390.43% 100.48% 78.85% 98.17% 98.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.86% 0.00% 3.96% 15.43%
Return on Invested Capital (ROIC)		 -453.13% -205.33% -824.79% -501.28% -414.59% -69.88% -20.89% -18,685.53% 0.00% 4,107.91% 20,765.80%
ROIC Less NNEP Spread (ROIC-NNEP)		 -453.71% -189.19% -819.84% -491.31% -377.52% 51.90% -28.02% -18,879.82% 0.00% 4,104.57% 20,770.86%
Return on Net Nonoperating Assets (RNNOA)		 377.30% 158.85% 627.99% 319.14% 209.42% -20.94% 5.72% 18,656.60% 0.00% -4,075.87% -20,650.18%
Return on Equity (ROE)		 -75.83% -46.48% -196.80% -182.13% -205.18% -90.82% -15.17% -28.93% 34.81% 32.04% 115.61%
Cash Return on Invested Capital (CROIC)		 -212.44% -234.58% -230.56% -240.86% -215.99% -157.45% -122.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.17% -28.59% -105.95% -76.76% -128.18% -20.25% -0.60% 91.55% -1.74% 17.39% 68.35%
Return on Assets (ROA)		 -45.88% -29.39% -104.30% -84.90% -133.24% -39.99% -3.81% 89.36% -0.76% 16.40% 56.69%
Return on Common Equity (ROCE)		 -75.83% -46.48% -196.80% -182.13% -205.18% -90.82% -15.17% -28.93% 34.81% 32.04% 115.61%
Return on Equity Simple (ROE_SIMPLE)		 -30.25% 0.00% -101.30% -205.70% -128.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -11 -14 -17 -19 -11 -3.75 -69 2.90 8.95 44
NOPAT Margin		 -371.50% -82.12% -418.69% -374.39% -517.30% -89.61% -18.40% -266.63% 11.13% 26.22% 121.75%
Net Nonoperating Expense Percent (NNEP)		 0.58% -16.14% -4.96% -9.97% -37.07% -121.78% 7.13% 194.29% -3.35% 3.34% -5.06%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.14% - - - -10.88% -3.71% -38.79% 1.49% 4.13% 21.43%
Cost of Revenue to Revenue		 4.97% 9.50% 5.11% 80.31% 62.33% 11.34% 6.59% 47.83% 4.75% 4.45% 5.24%
SG&A Expenses to Revenue		 200.97% 113.44% 289.96% 283.30% 438.65% 133.90% 95.80% 80.30% 64.98% 59.65% 57.38%
R&D to Revenue		 424.77% 88.40% 358.45% 236.48% 296.21% 69.35% 15.97% 13.26% 13.17% 7.68% 12.13%
Operating Expenses to Revenue		 625.73% 207.82% 693.02% 554.53% 776.67% 216.67% 119.69% 326.65% 79.35% 68.25% -49.21%
Earnings before Interest and Taxes (EBIT)		 -12 -19 -17 -18 -32 -18 -0.49 77 -1.24 13 46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -19 -15 -16 -30 -16 0.85 77 -2.06 12 45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.42 3.83 4.30 6.31 5.23 11.22 9.88 4.11 4.01 3.26 2.66
Price to Tangible Book Value (P/TBV)		 2.42 0.00 0.00 0.00 0.00 0.00 0.00 4.57 4.39 3.51 2.81
Price to Revenue (P/Rev)		 9.87 8.64 7.58 8.66 14.91 18.85 9.99 7.77 6.33 4.74 4.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 182.20 15.11 6.06 4.41
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.55% 6.62% 16.50% 22.70%
Enterprise Value to Invested Capital (EV/IC)		 4.44 5.75 5.12 5.15 9.90 18.14 12.25 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.49 7.73 7.23 9.04 13.42 18.18 9.77 5.24 4.32 3.08 2.54
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.61 6.19 3.69 2.33
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.50 6.43 3.73 2.32
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.32
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.88 32.12 0.00 5.33
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.65 0.69 0.88 1.80 0.84 1.50 1.46 0.52 0.46 0.40 0.00
Long-Term Debt to Equity		 0.65 0.08 0.88 1.80 0.84 1.50 1.46 0.52 0.46 0.40 0.00
Financial Leverage		 -0.83 -0.84 -0.77 -0.65 -0.55 -0.40 -0.20 -0.99 -1.01 -0.99 -0.99
Leverage Ratio		 1.60 2.10 2.15 2.48 2.41 3.45 3.61 2.68 2.28 2.38 1.83
Compound Leverage Factor		 1.41 2.16 2.12 2.73 2.50 3.88 14.08 2.69 1.79 2.34 1.79
Debt to Total Capital		 39.40% 40.87% 46.83% 64.23% 45.78% 60.00% 59.43% 34.11% 31.53% 28.59% 0.00%
Short-Term Debt to Total Capital		 0.00% 36.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 39.40% 4.84% 46.83% 64.23% 45.78% 60.00% 59.43% 34.11% 31.53% 28.59% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 60.60% 59.13% 53.17% 35.77% 54.22% 40.00% 40.57% 65.89% 68.47% 71.41% 100.00%
Debt to EBITDA		 -1.87 -0.89 -0.87 -0.94 -0.73 -0.75 -0.95 1.98 1.04 0.70 0.00
Net Debt to EBITDA		 1.69 0.52 0.20 -0.15 0.45 0.20 0.14 -5.13 -2.87 -2.00 0.00
Long-Term Debt to EBITDA		 -1.87 -0.11 -0.87 -0.94 -0.73 -0.75 -0.95 1.98 1.04 0.70 0.00
Debt to NOPAT		 -1.43 -1.23 -1.07 -1.11 -0.97 -0.98 -1.19 -4.12 -1.06 -1.02 0.00
Net Debt to NOPAT		 1.29 0.72 0.24 -0.17 0.60 0.26 0.17 10.67 2.93 2.93 0.00
Long-Term Debt to NOPAT		 -1.43 -0.15 -1.07 -1.11 -0.97 -0.98 -1.19 -4.12 -1.06 -1.02 0.00
Altman Z-Score		 -1.21 -2.08 -2.55 -3.13 -1.65 -1.90 -1.67 1.86 1.27 1.55 4.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.31 1.18 2.10 2.00 2.88 2.53 3.02 7.85 8.62 5.68 4.89
Quick Ratio		 6.23 1.15 2.04 1.91 2.82 2.35 2.79 7.66 8.29 5.46 4.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -39 -62 -64 -64 -24 2.44 2.95 12 72 55 107
Operating Cash Flow to CapEx		 -2,690.70% -22,441.67% 0.00% 0.00% 0.00% 0.00% -8,305.05% -1,690.61% 850.00% 5,014.55% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -113.92 0.00 -34.98 -19.31 1.08 2.07 0.00 0.00 232.69 122.38
Operating Cash Flow to Interest Expense		 0.00 -29.49 0.00 -10.39 -14.36 -7.17 -5.77 0.00 0.00 23.37 7.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -29.62 0.00 -10.39 -14.36 -7.17 -5.84 0.00 0.00 22.91 7.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.19 0.21 0.19 0.15 0.13 0.25 0.31 0.37 0.46 0.54
Accounts Receivable Turnover		 2.01 2.14 3.44 2.06 2.76 1.69 3.88 4.56 6.85 6.31 7.05
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.89 7.00
Fixed Asset Turnover		 22.17 35.90 38.51 34.66 39.21 43.25 72.67 97.13 154.13 252.00 287.06
Accounts Payable Turnover		 0.11 0.13 0.18 0.38 0.43 0.28 0.42 0.96 0.92 0.89 1.15
Days Sales Outstanding (DSO)		 181.92 170.64 106.21 177.04 132.03 215.53 94.07 80.08 53.27 57.88 51.81
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.08 52.17
Days Payable Outstanding (DPO)		 3,272.75 2,903.54 2,003.72 959.19 851.15 1,325.23 862.96 380.82 397.19 410.29 316.13
Cash Conversion Cycle (CCC)		 -3,090.83 -2,732.90 -1,897.51 -782.15 -719.12 -1,109.70 -768.89 -300.75 -343.92 -311.33 -212.16
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 28 37 39 42 33 24 32 -40 -36 -22 -31
Invested Capital Turnover		 1.22 2.50 1.97 1.34 0.80 0.78 1.14 70.08 -62.37 156.69 170.56
Increase / (Decrease) in Invested Capital		 29 52 50 48 5.28 -13 -6.71 -81 -69 -46 -63
Enterprise Value (EV)		 124 212 200 214 329 429 397 325 365 327 310
Market Capitalization		 164 237 210 205 365 445 405 482 534 504 547
Book Value per Share		 $1.99 $1.71 $1.35 $0.78 $1.33 $0.74 $0.76 $2.14 $2.37 $2.75 $3.51
Tangible Book Value per Share		 $1.99 ($0.33) ($0.65) ($0.92) ($0.11) ($0.64) ($0.57) $1.93 $2.17 $2.55 $3.32
Total Capital		 111 105 92 91 129 99 101 178 194 217 206
Total Debt		 44 43 43 58 59 60 60 61 61 62 0.00
Total Long-Term Debt		 44 5.07 43 58 59 60 60 61 61 62 0.00
Net Debt		 -40 -25 -9.72 9.07 -37 -16 -8.63 -157 -169 -177 -237
Capital Expenditures (CapEx)		 0.17 0.07 0.00 0.00 0.00 0.00 0.10 0.21 0.55 0.11 -0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 32 -17 -20 -19 -24 -18 -8.03 -5.11 -0.51 -7.28 -18
Debt-free Net Working Capital (DFNWC)		 115 51 33 30 65 52 55 198 199 184 183
Net Working Capital (NWC)		 115 13 33 30 65 52 55 198 199 184 183
Net Nonoperating Expense (NNE)		 -0.39 9.28 2.28 3.27 14 25 -0.65 -144 3.44 -3.22 6.21
Net Nonoperating Obligations (NNO)		 -40 -25 -9.72 9.07 -37 -16 -8.63 -157 -169 -177 -237
Total Depreciation and Amortization (D&A)		 0.06 0.79 1.56 1.56 1.62 1.65 1.34 0.90 -0.82 -0.50 -0.26
Debt-free, Cash-free Net Working Capital to Revenue		 192.43% -61.25% -71.22% -79.43% -99.70% -74.26% -19.79% -8.23% -0.60% -6.84% -14.45%
Debt-free Net Working Capital to Revenue		 696.12% 185.42% 119.02% 128.51% 265.27% 220.07% 134.52% 318.45% 235.82% 172.57% 149.60%
Net Working Capital to Revenue		 696.12% 48.13% 119.02% 128.51% 265.27% 220.07% 134.52% 318.45% 235.82% 172.57% 149.60%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.40) ($0.54) ($0.40) ($0.48) ($0.69) ($0.71) ($0.06) $1.24 ($0.01) $0.23 $0.62
Adjusted Weighted Average Basic Shares Outstanding		 34.72M 35.45M 41.78M 41.90M 47.81M 46.25M 54.10M 54.78M 55.95M 55.31M 58.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $1.21 ($0.01) $0.00 $0.60
Adjusted Weighted Average Diluted Shares Outstanding		 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M 54.68M 56.32M 55.95M 57.26M 60.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M 54.68M 56.14M 56.30M 58.71M 59.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -11 -14 -17 -19 -11 -3.75 -12 2.90 8.95 7.47
Normalized NOPAT Margin		 -371.50% -82.12% -418.69% -374.39% -517.30% -89.61% -18.40% -46.28% 11.13% 26.22% 20.62%
Pre Tax Income Margin		 -351.99% -153.96% -487.36% -446.28% -899.19% -169.13% -9.40% 297.15% -3.75% 37.12% 123.70%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -35.30 0.00 -9.79 -25.31 -7.98 -0.34 0.00 0.00 54.67 52.03
NOPAT to Interest Expense		 0.00 -19.36 0.00 -9.05 -15.13 -4.76 -2.63 0.00 0.00 37.91 50.23
EBIT Less CapEx to Interest Expense		 0.00 -35.43 0.00 -9.79 -25.31 -7.98 -0.41 0.00 0.00 54.20 52.04
NOPAT Less CapEx to Interest Expense		 0.00 -19.49 0.00 -9.05 -15.13 -4.76 -2.70 0.00 0.00 37.44 50.23
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -16.56% -7.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Zevra Therapeutics (NASDAQ: ZVRA) shows a much improved revenue and profitability profile in Q1 2026, but the quarter also highlights a business that remains dependent on non-operating items and balance-sheet restructuring. Over the last several quarters, the company has moved from recurring operating losses to meaningful quarterly operating profits, while maintaining a large cash and investment position. That said, results can be lumpy, and financing/debt activity has been material.

  • Revenue growth accelerated again in Q1 2026. Revenue rose to $36.2 million from $34.1 million in Q4 2025 and $20.4 million in Q1 2025, showing a clear upward trend year over year.
  • Gross profit remained strong. Q1 2026 gross profit was $34.3 million, implying a very high gross margin and suggesting the core revenue mix is attractive.
  • Operating income turned highly positive in Q1 2026. The company reported $52.1 million of operating income, helped by a large “other special charges / (income)” benefit.
  • Cash and investments remain substantial. At quarter-end, Zevra held $95.6 million of cash and equivalents plus $105.0 million of short-term investments, along with $36.1 million of long-term investments.
  • Liquidity improved sharply during the quarter. Net cash from operations was $6.1 million, and net cash increased by $33.2 million in the quarter.
  • Debt was reduced significantly in Q1 2026. The company repaid $60.1 million of debt, which helped improve the balance sheet compared with prior periods.
  • Equity improved from the prior quarter. Total common equity rose to $205.8 million from $133.2 million in Q3 2025.
  • Quarterly earnings were boosted by unusual items. Q1 2026 net income of $37.9 million was much higher than the underlying operating trend would suggest, so investors should not assume this level is fully recurring.
  • Investing cash flow was driven by portfolio activity and divestitures. The company generated $79.6 million of investing cash flow, largely from sale/maturity of investments and divestitures rather than from core business investment returns.
  • Cost structure is still volatile. SG&A and R&D spending remain meaningful, and results have swung sharply from loss to profit across recent quarters.

Looking at the trend over the last four years, Zevra has made real progress on the top line. Quarterly revenue has climbed from roughly $3.2 million in Q1 2023 to $36.2 million in Q1 2026. That’s a major improvement and the clearest positive signal in the data.

Profitability, however, remains uneven. In 2024 and early 2025, the company posted a mix of losses and one very large profit quarter, while Q1 2026 again showed a strong profit aided by special items. Operating income has improved materially versus 2023 and early 2024, but the path has not been linear.

The balance sheet is much stronger than it was a year ago, but the structure changed materially. In Q3 2025, total liabilities were $137.0 million versus $72.8 million in Q1 2026, while equity increased from $133.2 million to $205.8 million. Long-term debt fell from $61.3 million in Q3 2025 to zero in Q1 2026, which is a meaningful de-risking event.

From a retail investor perspective, the key question is sustainability. Zevra appears to have a healthier liquidity position and better operating momentum than it did in 2023–2024, but earnings can still be distorted by one-time items, investment gains/losses, and restructuring effects. The company’s next few quarters will help show whether revenue growth and operating leverage are becoming more consistent.

06/23/26 09:48 PM ETAI Generated. May Contain Errors.

Zevra Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zevra Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Zevra Therapeutics' net income appears to be on a downward trend, with a most recent value of $83.23 million in 2025, falling from -$54.66 million in 2015. The previous period was -$105.51 million in 2024. Check out Zevra Therapeutics' forecast to explore projected trends and price targets.

Zevra Therapeutics' total operating income in 2025 was -$62.94 million, based on the following breakdown:
  • Total Gross Profit: $89.99 million
  • Total Operating Expenses: $152.93 million

Over the last 10 years, Zevra Therapeutics' total revenue changed from $0.00 in 2015 to $106.47 million in 2025, a change of 10,647,000,000.0%.

Zevra Therapeutics' total liabilities were at $130.07 million at the end of 2025, a 6.1% decrease from 2024, and a 101.0% increase since 2015.

In the past 10 years, Zevra Therapeutics' cash and equivalents has ranged from $3.22 million in 2019 to $112.35 million in 2021, and is currently $62.41 million as of their latest financial filing in 2025.

Over the last 10 years, Zevra Therapeutics' book value per share changed from -0.70 in 2015 to 2.75 in 2025, a change of -492.2%.


Related Companies

Financial statements for NASDAQ:ZVRA last updated on 6/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel